Embryotoxicity and Toxicokinetics of the Antimalarial Artesunate in Rats

다국어 초록 (Multilingual Abstract)

This study was conducted to investigate the potential embryo-fetal toxicity and toxicokinetics of the antimalarial agent artesunate (ARTS) in Sprague-Dawley rats. Pregnant rats were administered ARTS daily from gestational day 6~15 via oral gavage, at test doses of 0, 2, 4, or 8 mg/kg (22 females per group). The fetuses were examined for external, visceral, and skeletal abnormalities on gestational day 20. With regard to the dams, there were no deaths, treatment-related clinical signs, changes in body weight, or food intake in any of the treatment groups. There were no treatment-related gross findings at necropsy in any treatment group. In the 8 mg/kg group, there was a decrease in gravid uterine weight and in the weight of female fetuses. There was also an increase in fetal deaths (primarily late resorptions) and an increase in post-implantation losses (37%) at 8 mg/kg. An increase in the incidence of visceral and skeletal variations at 4 and 8 mg/kg was observed. These defects included minor changes in the appearance of the kidney and thymus, as well as absent ribs or thoracic vertebrae. Toxicokinetics were assessed in a parallel study, using 4 mated females per group. Using liquid chromatography-mass spectrometry (LC-MS) analysis, the concentration of ARTS and its metabolite dihydroartemisinin (DHA) were quantified in plasma from rats on gestational days 5, 6, 10, and 15. Amniotic fluid was assayed for ARTS and DHA on gestational day 15. There was evidence of rapid conversion of ARTS to the metabolite DHA in maternal plasma, since ARTS could not be consistently detected in plasma at the three doses tested. ARTS and DHA were not detected in amniotic fluid at gestational day 15, indicating limited placental transfer of the two agents. The embryofetal no-observable-adverse-effect level (NOAEL) of the test item was considered to be 8 mg/kg/day for dams, and 2 mg/kg/day for embryo-fetal development.

참고문헌 (Reference)

• 1 Deen, J. L., "The safety of the combination artesunate and pyrimethamine-sulfadoxine given during pregnancy" 95 : 424-428, 2001
• 2 Ilett, K. F., "The pharmacokinetic properties of intramuscular artesunate and rectal dihydroartemisinin in uncomplicated falciparum malaria" 53 : 23-30, 2002
• 3 Makris, S. L., "Terminology of developmental abnormalities in common laboratory mammals (Version 2)" 86 : 227-327, 2009
• 4 Li, Q., "Severe embryotoxicity of artemisinin derivatives in experimental animals, but possibly safe in pregnant women" 15 : 40-57, 2010
• 5 Bialek, R., "Parasitic diseases in pregnancy and congenital parasitos. Part 1. Protozoan infections (Review, German)" 203 : 55-62, 1999
• 6 Wilson, J. G., "Methods for administering agents and detecting malformations in experimental animals, In: Teratology, Principles and Techniques" University of Chicago 262-277, 1965
• 7 Sarciron, M. E., "Effect of artesunate, dihydroartemisinin, and an artesunate- dihyroartemisinin combination against Toxoplasma gondii" 62 : 73-76, 2000
• 8 White, T. E. K., "Early artesunate-induced changes in the rat embryo preceding embryolethality and embryotoxicity" 73 : 297-310, 2005
• 9 Clark, R. L., "Developmental toxicity of artesunate and an artesunate combination in the rat and rabbit" 71 : 380-394, 2004
• 10 Naik, H., "Development and validation of a high-performance liquid chromatography-mass spectroscopy assay for determination of artesunate and dihydroartemisinin in human plasma" 816 : 233-242, 2005
• 11 Chahoud, I., "Correlation between maternal toxicity and embryo/fetal effects" 13 : 375-381, 1999
• 12 White, N. J., "Averting a malaria disaster" 353 : 1965-1967, 1999
• 13 Barradell, L.B., "Artesunate. A review of its pharmacology and therapeutic efficacy in the treatment of malaria" 50 : 714-741, 1995
• 14 Meshnick, S. R., "Artemisinin: mechanisms of action, resistance and toxicity" 32 : 1655-1660, 2002
• 15 MARTA., "Appendix B: Historical Control Data. In: Handbook of Developmental Toxicology" CRC 716-724, 1997
• 16 Motta, M., "Antimalarial agents in pregnancy" 359 : 524-525, 2002
• 17 Luzzi, G.A., "Adverse effects of antimalarials: An update" 8 : 295-311, 1993
• 18 Dawson, A. B., "A note on the staining of the skeleton of cleared specimens with Alizarin Red S" 1 : 123-124, 1926
• 19 Nishimura, K., "A microdissection method for detecting thoracic visceral malformations in mouse and rat fetuses" 14 : 23-40, 1974